THE BINDING SITE OF AMINERGIC GP ROTEIN-COUPLED RECEPTORS:

[1]  K. Neve,et al.  Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. , 2001, Molecular pharmacology.

[2]  J. Ballesteros,et al.  Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. , 2001, Molecular pharmacology.

[3]  D. Larhammar,et al.  Site-directed mutagenesis of the 5-HT1B receptor increases the affinity of 5-HT for the agonist low-affinity conformation and reduces the intrinsic activity of 5-HT. , 2001, European journal of pharmacology.

[4]  J. Saldanha,et al.  The conformational switch in muscarinic acetylcholine receptors. , 2001, Life sciences.

[5]  D. Sibley,et al.  The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. , 2001, The Journal of pharmacology and experimental therapeutics.

[6]  T. Sakmar,et al.  Rhodopsin: structural basis of molecular physiology. , 2001, Physiological reviews.

[7]  C R Ganellin,et al.  Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain , 2000, British journal of pharmacology.

[8]  J. Ballesteros,et al.  The Forgotten Serine , 2000, The Journal of Biological Chemistry.

[9]  B. Roth,et al.  Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. , 2000, Molecular pharmacology.

[10]  J. Ballesteros,et al.  The first transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. , 2000, Biochemistry.

[11]  P. Pauwels,et al.  Coupling of Canine Serotonin 5‐HT1B and 5‐HT1D Receptor Subtypes to the Formation of Inositol Phosphates by Dual Interactions with Endogenous Gi/o and Recombinant Gα15 Proteins , 2000, Journal of neurochemistry.

[12]  K. Neve,et al.  CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors. , 2000, Journal of medicinal chemistry.

[13]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[14]  E. Meng,et al.  Rhodopsin Sees the Light , 2000, Science.

[15]  K. Page,et al.  Scanning mutagenesis identifies amino acid side chains in transmembrane domain 5 of the M(1) muscarinic receptor that participate in binding the acetyl methyl group of acetylcholine. , 2000, Molecular pharmacology.

[16]  B. Roth,et al.  A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. , 2000, The Journal of pharmacology and experimental therapeutics.

[17]  S. Lazareno,et al.  Allosteric interactions between the antagonist prazosin and amiloride analogs at the human alpha(1A)-adrenergic receptor. , 2000, Molecular pharmacology.

[18]  A. IJzerman,et al.  TinyGRAP database: a bioinformatics tool to mine G-protein-coupled receptor mutant data. , 1999, Trends in pharmacological sciences.

[19]  J. Ballesteros,et al.  Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. , 1999, Molecular pharmacology.

[20]  J. Ellis,et al.  Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. , 1999, Molecular pharmacology.

[21]  E. Hulme,et al.  Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function. , 1999, Molecular pharmacology.

[22]  A. IJzerman,et al.  Study of Interaction between Agonists and Asn293 in Helix VI of Human β2-Adrenergic Receptor , 1999 .

[23]  R. Leurs,et al.  Mutational Analysis of the Antagonist-binding Site of the Histamine H1 Receptor* , 1999, The Journal of Biological Chemistry.

[24]  H. Weinstein,et al.  The Functional Microdomain in Transmembrane Helices 2 and 7 Regulates Expression, Activation, and Coupling Pathways of the Gonadotropin-releasing Hormone Receptor* , 1999, The Journal of Biological Chemistry.

[25]  C. Guenet,et al.  Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site. , 1999, European journal of pharmacology.

[26]  D. Larhammar,et al.  Identification of an amino acid residue important for binding of methiothepin and sumatriptan to the human 5-HT1B receptor , 1999 .

[27]  M. Scheinin,et al.  Chloroethylclonidine and 2-Aminoethyl Methanethiosulfonate Recognize Two Different Conformations of the Human α2A-Adrenergic Receptor* , 1999, The Journal of Biological Chemistry.

[28]  J. Ballesteros,et al.  Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment. , 1999, Biochemistry.

[29]  Thomas Gudermann,et al.  Structural basis of G protein-coupled receptor function , 1999, Molecular and Cellular Endocrinology.

[30]  E C Hulme,et al.  The Functional Topography of Transmembrane Domain 3 of the M1 Muscarinic Acetylcholine Receptor, Revealed by Scanning Mutagenesis* , 1999, The Journal of Biological Chemistry.

[31]  D. Sibley,et al.  Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants. , 1999, Pharmacogenetics.

[32]  Xi-Ping Huang,et al.  Roles of threonine 192 and asparagine 382 in agonist and antagonist interactions with M1 muscarinic receptors , 1999, British journal of pharmacology.

[33]  W. Vogel,et al.  Double mutant cycle analysis of aspartate 69, 97, and 103 to asparagine mutants in the m2 muscarinic acetylcholine receptor. , 1999, Archives of biochemistry and biophysics.

[34]  P. Pauwels,et al.  Chimeric receptor analysis of the ketanserin binding site in the human 5-Hydroxytryptamine1D receptor: importance of the second extracellular loop and fifth transmembrane domain in antagonist binding. , 1998, Molecular pharmacology.

[35]  D. Colquhoun,et al.  Binding, gating, affinity and efficacy: The interpretation of structure‐activity relationships for agonists and of the effects of mutating receptors , 1998, British journal of pharmacology.

[36]  F. Monsma,et al.  Identification of Residues in Transmembrane Regions III and VI that Contribute to the Ligand Binding Site of the Serotonin 5‐HT6 Receptor , 1998, Journal of neurochemistry.

[37]  B. Roth,et al.  5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. , 1998, Pharmacology & therapeutics.

[38]  T. Nagao,et al.  Identification of a key amino acid of the beta2-adrenergic receptor for high affinity binding of salmeterol. , 1998, Molecular pharmacology.

[39]  Glen L Alberts,et al.  Contributions of cysteine 114 of the human D3 dopamine receptor to ligand binding and sensitivity to external oxidizing agents , 1998, British journal of pharmacology.

[40]  K. Konvička,et al.  A proposed structure for transmembrane segment 7 of G protein-coupled receptors incorporating an asn-Pro/Asp-Pro motif. , 1998, Biophysical journal.

[41]  W. Im,et al.  Identification of transmembrane regions critical for ligand binding to the human D3 dopamine receptor using various D3/D1 transmembrane chimeras. , 1998, Molecular pharmacology.

[42]  M. Grossmann,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[43]  D. Larhammar,et al.  Mutagenesis of the human 5-HT1B receptor: differences from the closely related 5-HT1A receptor and the role of residue F331 in signal transduction. , 1998, Journal of receptor and signal transduction research.

[44]  P. Leff,et al.  Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. , 1998, Molecular pharmacology.

[45]  D. Larhammar,et al.  Site-directed mutagenesis of the human 5-HT1B receptor. , 1998, European journal of pharmacology.

[46]  S. Lazareno,et al.  Characterization of the allosteric interactions between antagonists and amiloride analogues at the human alpha2A-adrenergic receptor. , 1998, Molecular pharmacology.

[47]  Robert P. Millar,et al.  Functional Microdomains in G-protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[48]  H. Kase,et al.  Unique binding pocket for KW-4679 in the histamine H1 receptor. , 1998, European journal of pharmacology.

[49]  M. Scheinin,et al.  Chloroethylclonidine binds irreversibly to exposed cysteines in the fifth membrane-spanning domain of the human alpha2A-adrenergic receptor. , 1998, Molecular pharmacology.

[50]  K. Neve,et al.  Constitutive activity of a chimeric D2/D1 dopamine receptor. , 1997, Molecular pharmacology.

[51]  D. Sheehan,et al.  Site-directed mutagenesis on the m2 muscarinic acetylcholine receptor: the significance of Tyr403 in the binding of agonists and functional coupling. , 1997, Molecular pharmacology.

[52]  H Weinstein,et al.  Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor , 1997, The EMBO journal.

[53]  D. Nelson,et al.  Mutations of transmembrane IV and V serines indicate that all tryptamines do not bind to the rat 5-HT2A receptor in the same manner. , 1997, Brain research. Molecular brain research.

[54]  J. Baldwin,et al.  An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. , 1997, Journal of molecular biology.

[55]  Gebhard F. X. Schertler,et al.  Arrangement of rhodopsin transmembrane α-helices , 1997, Nature.

[56]  F. Monsma,et al.  Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor. , 1997, Molecular pharmacology.

[57]  B. Roth,et al.  Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. , 1997, Molecular pharmacology.

[58]  G. Liapakis,et al.  Constitutive Activation of the β2 Adrenergic Receptor Alters the Orientation of Its Sixth Membrane-spanning Segment* , 1997, The Journal of Biological Chemistry.

[59]  Marvin C. Gershengorn,et al.  Interactions between Conserved Residues in Transmembrane Helices 1, 2, and 7 of the Thyrotropin-releasing Hormone Receptor* , 1997, The Journal of Biological Chemistry.

[60]  R. Leurs,et al.  Study of the interaction between aryloxypropanolamines and Asn386 in helix VII of the human 5-hydroxytryptamine1A receptor. , 1997, Molecular pharmacology.

[61]  T. Sakmar,et al.  Functional Interaction of Transmembrane Helices 3 and 6 in Rhodopsin , 1996, The Journal of Biological Chemistry.

[62]  F. Fanelli,et al.  Amino acids of the α 1B‐adrenergic receptor involved in agonist binding: differences in docking catecholamines to receptor subtypes , 1996, FEBS letters.

[63]  B. Kobilka,et al.  Ligand stabilization of the beta 2 adrenergic receptor: effect of DTT on receptor conformation monitored by circular dichroism and fluorescence spectroscopy. , 1996, Biochemistry.

[64]  P. Jeffs,et al.  Phenylalanine in the second membrane-spanning domain of alpha 1A-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists. , 1996, Biochemistry.

[65]  D. Perez,et al.  Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding. , 1996, Molecular pharmacology.

[66]  H. Akil,et al.  Mutagenesis of residues adjacent to transmembrane prolines alters D1 dopamine receptor binding and signal transduction. , 1996, Molecular pharmacology.

[67]  S. Hoare,et al.  Regulation of D2 dopamine receptors by amiloride and amiloride analogs. , 1996, Molecular pharmacology.

[68]  H. Khorana,et al.  Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.

[69]  J. Ballesteros,et al.  Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice. , 1996, Biochemistry.

[70]  A. IJzerman,et al.  Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[71]  H Weinstein,et al.  Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. , 1996, Molecular pharmacology.

[72]  H Weinstein,et al.  Mapping the Binding Site Pocket of the Serotonin 5-Hydroxytryptamine2A Receptor , 1996, The Journal of Biological Chemistry.

[73]  J. Javitch,et al.  Differentiating dopamine D2 ligands by their sensitivities to modification of the cysteine exposed in the binding-site crevice. , 1996, Molecular pharmacology.

[74]  J. Wess,et al.  Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. , 1996, Molecular pharmacology.

[75]  M. Maze,et al.  Arrangement of Transmembrane Domains in Adrenergic Receptors , 1996, The Journal of Biological Chemistry.

[76]  J. Javitch,et al.  Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice. , 1995, Biochemistry.

[77]  H. Akil,et al.  Hydrophobic Residues of the D2 Dopamine Receptor Are Important for Binding and Signal Transduction , 1995, Journal of neurochemistry.

[78]  K. Catt,et al.  Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[79]  R. Leurs,et al.  Lysine200 located in the fifth transmembrane domain of the histamine H1 receptor interacts with histamine but not with all H1 agonists. , 1995, Biochemical and biophysical research communications.

[80]  J. Wess,et al.  Mutational Analysis of the Relative Orientation of Transmembrane Helices I and VII in G Protein-coupled Receptors (*) , 1995, The Journal of Biological Chemistry.

[81]  H Weinstein,et al.  Related Contribution of Specific Helix 2 and 7 Residues to Conformational Activation of the Serotonin 5-HT2A Receptor (*) , 1995, The Journal of Biological Chemistry.

[82]  T. Kenakin,et al.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.

[83]  K. Page,et al.  The functional role of the binding site aspartate in muscarinic acetylcholine receptors, probed by site-directed mutagenesis. , 1995, European journal of pharmacology.

[84]  Jonathan A Javitch,et al.  Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method , 1995, Neuron.

[85]  B. Roth,et al.  Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding. , 1995, Molecular pharmacology.

[86]  J. Rosenbusch,et al.  Structural basis for sugar translocation through maltoporin channels at 3.1 A resolution , 1995, Science.

[87]  L. Limbird,et al.  Mutation of an aspartate residue highly conserved among G-protein-coupled receptors results in nonreciprocal disruption of alpha 2-adrenergic receptor-G-protein interactions. A negative charge at amino acid residue 79 forecasts alpha 2A-adrenergic receptor sensitivity to allosteric modulation by mon , 1994, The Journal of biological chemistry.

[88]  J. Javitch,et al.  A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[89]  K. Jacobson,et al.  Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors. , 1994, The Journal of biological chemistry.

[90]  H Hayashi,et al.  Site-directed mutagenesis of the histamine H1 receptor: roles of aspartic acid107, asparagine198 and threonine194. , 1994, Biochemical and biophysical research communications.

[91]  J. Wess,et al.  Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. , 1994, The Journal of biological chemistry.

[92]  A. Karlin,et al.  Electrostatic potential of the acetylcholine binding sites in the nicotinic receptor probed by reactions of binding-site cysteines with charged methanethiosulfonates. , 1994, Biochemistry.

[93]  R. Leurs,et al.  Site-directed mutagenesis of the histamine H1-receptor reveals a selective interaction of asparagine207 with subclasses of H1-receptor agonists. , 1994, Biochemical and biophysical research communications.

[94]  M. Eck,et al.  Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor. , 1994, Molecular pharmacology.

[95]  L. Naylor,et al.  Structural Studies on D2 Dopamine Receptors: Mutation of a Histidine Residue Specifically Affects the Binding of a Subgroup of Substituted Benzamide Drugs , 1994, Journal of neurochemistry.

[96]  L. Naylor,et al.  Site-directed mutagenesis of Tyr417 in the rat D2 dopamine receptor. , 1994, Biochemical Society transactions.

[97]  R. Lefkowitz,et al.  A constitutively active mutant beta 2-adrenergic receptor is constitutively desensitized and phosphorylated. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[98]  R. Graham,et al.  The high affinity state of the beta 2-adrenergic receptor requires unique interaction between conserved and non-conserved extracellular loop cysteines. , 1994, The Journal of biological chemistry.

[99]  P. Evans,et al.  Agonist‐specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems. , 1994, The EMBO journal.

[100]  R. Lefkowitz,et al.  Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. , 1994, Molecular pharmacology.

[101]  D. Oprian,et al.  Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness , 1994, Nature.

[102]  E C Hulme,et al.  Acetylcholine mustard labels the binding site aspartate in muscarinic acetylcholine receptors. , 1994, The Journal of biological chemistry.

[103]  K Konvicka,et al.  A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. , 1994, Molecular pharmacology.

[104]  R. Loncharich,et al.  Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. , 1994, Molecular pharmacology.

[105]  J. Kraut,et al.  Long-range structural effects in a second-site revertant of a mutant dihydrofolate reductase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[106]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[107]  S. Green,et al.  A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. , 1993, The Journal of biological chemistry.

[108]  B. Kobilka,et al.  Amino acid substitutions at position 312 in the seventh hydrophobic segment of the beta 2-adrenergic receptor modify ligand-binding specificity. , 1993, Molecular pharmacology.

[109]  T. Gallaher,et al.  Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. , 1993, Molecular pharmacology.

[110]  B. Roth,et al.  A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors. , 1993, Molecular pharmacology.

[111]  Gebhard F. X. Schertler,et al.  Projection structure of rhodopsin , 1993, Nature.

[112]  P. Chanda,et al.  Identification of residues important for ligand binding to the human 5-hydroxytryptamine1A serotonin receptor. , 1993, Molecular pharmacology.

[113]  R. Lefkowitz,et al.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.

[114]  J. Wess,et al.  Functional role of proline and tryptophan residues highly conserved among G protein‐coupled receptors studied by mutational analysis of the m3 muscarinic receptor. , 1993, The EMBO journal.

[115]  E. Parker,et al.  A Single Amino Acid Difference Accounts for the Pharmacological Distinctions Between the Rat and Human 5‐Hydroxytryptamine1B Receptors , 1993, Journal of neurochemistry.

[116]  B. O'dowd,et al.  A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors , 1992, Nature.

[117]  H. Lester,et al.  The role of conserved aspartate and serine residues in ligand binding and in function of the 5‐HT1A receptor: A site‐directed mutation study , 1992, FEBS letters.

[118]  Yi-Jun Guo,et al.  Molecular basis for the interaction of histamine with the histamine H2 receptor. , 1992, The Journal of biological chemistry.

[119]  H. Akil,et al.  Site-directed mutagenesis of the human dopamine D2 receptor. , 1992, European journal of pharmacology.

[120]  N. Pollock,et al.  Serine mutations in transmembrane V of the dopamine D1 receptor affect ligand interactions and receptor activation. , 1992, The Journal of biological chemistry.

[121]  H. Kao,et al.  Site‐directed mutagenesis of a single residue changes the binding properties of the serotonin 5‐HT2 receptor from a human to a rat pharmacology , 1992, FEBS letters.

[122]  K. Neve,et al.  Contributions of Conserved Serine Residues to the Interactions of Ligands with Dopamine D2 Receptors , 1992, Journal of Neurochemistry.

[123]  C. Fraser,et al.  Site-directed mutagenesis of the rat m1 muscarinic acetylcholine receptor. Role of conserved cysteines in receptor function. , 1992, The Journal of biological chemistry.

[124]  B. Kobilka,et al.  Identification of a single amino acid residue responsible for the binding of a class of beta-adrenergic receptor antagonists to 5-hydroxytryptamine1A receptors. , 1992, Molecular pharmacology.

[125]  J. Wess,et al.  Site‐directed mutagenesis of the m3 muscarinic receptor: identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. , 1991, The EMBO journal.

[126]  S. Fuchs,et al.  Antipeptide antibodies localize N-(4-azido-3-[125I] iodophenethyl)spiperone binding to the carboxyl-terminal portion of the D2 dopamine receptor. , 1991, Molecular pharmacology.

[127]  B. Kobilka,et al.  A point mutation in the seventh hydrophobic domain of the alpha 2 adrenergic receptor increases its affinity for a family of beta receptor antagonists. , 1991, The Journal of biological chemistry.

[128]  K. Neve,et al.  Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. , 1991, Molecular pharmacology.

[129]  K. Neve,et al.  Regulation of dopamine D2 receptors by sodium and pH. , 1991, Molecular pharmacology.

[130]  C. Strader,et al.  Allele-specific activation of genetically engineered receptors. , 1991, The Journal of biological chemistry.

[131]  C. A. Guyer,et al.  An aspartate conserved among G-protein receptors confers allosteric regulation of alpha 2-adrenergic receptors by sodium. , 1990, The Journal of biological chemistry.

[132]  E. Hulme,et al.  Muscarinic acetylcholine receptors. Peptide sequencing identifies residues involved in antagonist binding and disulfide bond formation. , 1990, The Journal of biological chemistry.

[133]  C. Strader,et al.  Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. , 1989, The Journal of biological chemistry.

[134]  M. Caron,et al.  Localization of the fourth membrane spanning domain as a ligand binding site in the human platelet alpha 2-adrenergic receptor. , 1989, Biochemistry.

[135]  C. Strader,et al.  Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. , 1988, The Journal of biological chemistry.

[136]  C. Slaughter,et al.  The catecholamine binding site of the beta-adrenergic receptor is formed by juxtaposed membrane-spanning domains. , 1988, The Journal of biological chemistry.

[137]  M. Caron,et al.  Chimeric alpha 2-,beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. , 1988, Science.

[138]  C. Strader,et al.  Identification and sequence of a binding site peptide of the beta 2-adrenergic receptor. , 1988, Biochemistry.

[139]  C. Strader,et al.  Identification of residues required for ligand binding to the beta-adrenergic receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[140]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[141]  Harel Weinstein,et al.  Three-dimensional representations of G protein-coupled receptor structures and mechanisms. , 2002, Methods in enzymology.

[142]  D. Sibley,et al.  Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. , 2000, Molecular pharmacology.

[143]  H. Kikkawa,et al.  The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. , 1998, Molecular pharmacology.

[144]  D. Perez,et al.  Molecular mechanisms of ligand binding and activation in alpha 1-adrenergic receptors. , 1998, Advances in pharmacology.

[145]  M. P. Turpin,et al.  Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system. , 1998, Journal of receptor and signal transduction research.

[146]  A. Karlin,et al.  Substituted-cysteine accessibility method. , 1998, Methods in enzymology.

[147]  R. Glennon,et al.  The binding of propranolol at 5-hydroxytryptamine1D beta T355N mutant receptors may involve formation of two hydrogen bonds to asparagine. , 1996, Molecular pharmacology.

[148]  J. Hénichart,et al.  Pharmacological and functional characterisation of the wild-type and site-directed mutants of the human H1 histamine receptor stably expressed in CHO cells. , 1995, Journal of receptor and signal transduction research.

[149]  S. Lazareno,et al.  Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. , 1995, Molecular pharmacology.

[150]  C. Strader,et al.  Structure-function analysis of the beta-adrenergic receptor. , 1988, Cold Spring Harbor symposia on quantitative biology.